Our Solution

Ensilication® is a patent protected, novel method for encasing thermally unstable biomolecules within a silica network to prevent degradation at temperatures from –80 to +50 °C, and improved shelf-life.

The technology is designed for both existing, and new biopharmaceutical formulations. It produces thermally stable products that do not rely on cold-chain logistics, preventing wastage, improving shelf-life and increasing the accessibility of biological therapeutics and diagnostics globally.

Unlike other stabilisation technologies, ensilication does not rely on lyophilisation or any harsh conditions. The technology is designed for both existing, and new biopharmaceutical formulations. It produces thermally stable products that do not rely on cold-chain logistics.

The Problem

At present, antibodies, vaccines, and other biological products are shipped and stored around the world using a global network of refrigerators and freezers known as the cold chain.

 This network is expensive to operate and prone to failure, resulting in significant levels of spoilage, resulting in 1.5M infants dying each year. Cold chain failures are reported to cost the pharmaceutical industry ~$35B annually.

The cold chain is equally as costly for our planet as it is for human and animal life, being  responsible for up to 90% of vaccination programme emissions, producing over 1.5B tonnes of CO2 in 2021 alone.